Keywords: B-cell lymphoma, Pharmacyclics, Janssen Johnson & Johnson, PCI-32765, Decision Resources

Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication

Article | 19 February 2012

Print This

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC) and Janssen Biotech’s (a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in